1887

Abstract

Oncolytic adenoviruses (OAds) have attracted much attention as novel anticancer agents. Numerous studies have examined the antitumour effects of combinational use of an OAd and anticancer agents; however, few chemical compounds enhancing OAd infection have been reported. In this study, we screened a food and drug administration (FDA)-approved drug library containing 1134 small chemical compounds to identify chemical compounds that enhance OAd replication in human tumour cells. We found that domperidone, a dopamine D2 receptor antagonist, significantly enhanced the replication of an OAd in human tumour cells, including human pancreatic tumour cells, by two–fivefold, resulting in improvement of OAd-mediated tumour cell killing activities. The E1A mRNA levels were significantly increased in domperidone-pre-treated cells following OAd infection, which contributed to the promotion of OAd replication. However, mRNA levels of the dopamine D2 receptor (DRD2), which is known to be a target molecule of domperidone, were undetectable in most of the tumour cells by real-time reverse transcription (RT)-PCR analysis, indicating that domperidone promoted OAd replication by acting on a molecule other than DRD2. This study provides important clues for the improvement of OAd-mediated cancer therapy.

Funding
This study was supported by the:
  • Japan Agency for Medical Research and Development (Award JP21am0101084)
    • Principle Award Recipient: HiroyukiMizuguchi
  • Japan Society for the Promotion of Science London (Award 20H00664)
    • Principle Award Recipient: HiroyukiMizuguchi
Loading

Article metrics loading...

/content/journal/jgv/10.1099/jgv.0.001752
2022-06-22
2022-07-06
Loading full text...

Full text loading...

References

  1. Twumasi-Boateng K, Pettigrew JL, Kwok YYE, Bell JC, Nelson BH. Oncolytic viruses as engineering platforms for combination immunotherapy. Nat Rev Cancer 2018; 18:419–432 [View Article] [PubMed]
    [Google Scholar]
  2. Kaufman HL, Kohlhapp FJ, Zloza A. Oncolytic viruses: A new class of immunotherapy drugs. Nat Rev Drug Discov 2015; 14:642–662 [View Article] [PubMed]
    [Google Scholar]
  3. Conry RM, Westbrook B, McKee S, Norwood TG. Talimogene laherparepvec: First in class oncolytic virotherapy. Hum Vaccin Immunother 2018; 14:839–846 [View Article] [PubMed]
    [Google Scholar]
  4. Cervera-Carrascon V, Havunen R, Hemminki A. Oncolytic adenoviruses: a game changer approach in the battle between cancer and the immune system. Expert Opin Biol Ther 2019; 19:443–455 [View Article] [PubMed]
    [Google Scholar]
  5. Bramante S, Koski A, Kipar A, Diaconu I, Liikanen I et al. Serotype chimeric oncolytic adenovirus coding for GM-CSF for treatment of sarcoma in rodents and humans. Int J Cancer 2014; 135:720–730 [View Article] [PubMed]
    [Google Scholar]
  6. Kirn D. Oncolytic virotherapy for cancer with the adenovirus dl1520 (Onyx-015): results of phase I and II trials. Expert Opin Biol Ther 2001; 1:525–538 [View Article] [PubMed]
    [Google Scholar]
  7. Mizuguchi H, Kay MA, Hayakawa T. In vitro ligation-based cloning of foreign DNAs into the E3 and E1 deletion regions for generation of recombinant adenovirus vectors. Biotechniques 2001; 30:1112–1114 [View Article] [PubMed]
    [Google Scholar]
  8. Sakurai F, Nishimae F, Takayama K, Mizuguchi H. Optimization of an E1A gene expression cassette in an oncolytic adenovirus for efficient tumor cell killing activity. Anticancer Res 2021; 41:773–782 [View Article] [PubMed]
    [Google Scholar]
  9. Koizumi N, Yamaguchi T, Kawabata K, Sakurai F, Sasaki T et al. Fiber-modified adenovirus vectors decrease liver toxicity through reduced IL-6 production. J Immunol 2007; 178:1767–1773 [View Article] [PubMed]
    [Google Scholar]
  10. Kishimoto H, Kojima T, Watanabe Y, Kagawa S, Fujiwara T et al. In vivo imaging of lymph node metastasis with telomerase-specific replication-selective adenovirus. Nat Med 2006; 12:1213–1219 [View Article] [PubMed]
    [Google Scholar]
  11. Maizel JV, White DO, Scharff MD. The polypeptides of adenovirus. Virology 1968; 36:115–125 [View Article] [PubMed]
    [Google Scholar]
  12. Mizuguchi H, Koizumi N, Hosono T, Utoguchi N, Watanabe Y et al. A simplified system for constructing recombinant adenoviral vectors containing heterologous peptides in the HI loop of their fiber knob. Gene Ther 2001; 8:730–735 [View Article] [PubMed]
    [Google Scholar]
  13. Kawashima T, Kagawa S, Kobayashi N, Shirakiya Y, Umeoka T et al. Telomerase-specific replication-selective virotherapy for human cancer. Clin Cancer Res 2004; 10:285–292 [View Article] [PubMed]
    [Google Scholar]
  14. Barone JA. Domperidone: A peripherally acting dopamine2-receptor antagonist. Ann Pharmacother 1999; 33:429–440 [View Article] [PubMed]
    [Google Scholar]
  15. Reddymasu SC, Soykan I, McCallum RW. Domperidone: review of pharmacology and clinical applications in gastroenterology. Am J Gastroenterol 2007; 102:2036–2045 [View Article] [PubMed]
    [Google Scholar]
  16. Frisch SM, Mymryk JS. Adenovirus-5 E1A: paradox and paradigm. Nat Rev Mol Cell Biol 2002; 3:441–452 [View Article] [PubMed]
    [Google Scholar]
  17. Guse K, Dias JD, Bauerschmitz GJ, Hakkarainen T, Aavik E et al. Luciferase imaging for evaluation of oncolytic adenovirus replication in vivo. Gene Ther 2007; 14:902–911 [View Article] [PubMed]
    [Google Scholar]
  18. Kanai Y, Kawagishi T, Matsuura Y, Kobayashi T. In Vivo Live Imaging of Oncolytic Mammalian Orthoreovirus Expressing NanoLuc Luciferase in Tumor Xenograft Mice. J Virol 2019; 93:e00401-19 [View Article] [PubMed]
    [Google Scholar]
  19. Davydova J, Gavrikova T, Brown EJ, Luo X, Curiel DT et al. In vivo bioimaging tracks conditionally replicative adenoviral replication and provides an early indication of viral antitumor efficacy. Cancer Sci 2010; 101:474–481 [View Article] [PubMed]
    [Google Scholar]
  20. Branton PE, Rowe DT. Stabilities and interrelations of multiple species of human adenovirus type 5 early region 1 proteins in infected and transformed cells. J Virol 1985; 56:633–638 [View Article]
    [Google Scholar]
  21. Kamath A, Rai KM, Shreyas R, Saxena PUP, Banerjee S. Effect of domperidone, ondansetron, olanzapine-containing antiemetic regimen on QTC interval in patients with malignancy: a prospective, observational, single-group, assessor-blinded study. Sci Rep 2021; 11:445 [View Article] [PubMed]
    [Google Scholar]
  22. Huang YC, Colaizzi JL, Bierman RH, Woestenborghs R, Heykants JJ. Pharmacokinetics and dose proportionality of domperidone in healthy volunteers. J Clin Pharmacol 1986; 26:628–632 [View Article] [PubMed]
    [Google Scholar]
  23. Bruera E, Villamayor R, Roca E, Barugel M, Tronge J et al. Q-T interval prolongation and ventricular fibrillation with i.v. domperidone. Cancer Treat Rep 1986; 70:545–546 [PubMed]
    [Google Scholar]
  24. Libertini S, Iacuzzo I, Ferraro A, Vitale M, Bifulco M et al. Lovastatin enhances the replication of the oncolytic adenovirus dl1520 and its antineoplastic activity against anaplastic thyroid carcinoma cells. Endocrinology 2007; 148:5186–5194 [View Article] [PubMed]
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jgv/10.1099/jgv.0.001752
Loading
/content/journal/jgv/10.1099/jgv.0.001752
Loading

Data & Media loading...

Supplements

Supplementary material 1

PDF

Most cited this month Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error